Streetbeat News

Products Services

VALN

Valneva SE announced that the results of two Phase 2 clinical trials for its Lyme disease vaccine candidate, VLA15, have been published in 'The Lancet Infectious Diseases'. These trials, along with a third Phase 2 trial in pediatric participants, support the design of the current pivotal Phase 3 trial, VALOR.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:46 pm

ARWR

Arrowhead Pharmaceuticals shares are trading higher following positive topline results from the Phase 3 PALISADE study of plozasiran in patients with familial chylomicronemia syndrome. The company also met all key secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:46 pm

GPCR

Structure Therapeutics shares are trading higher following the release of topline data from its Phase 2a study of GSBR-1290.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:38 pm

MBOT

Microbot Medical Inc. (NASDAQ:MBOT) shares surged after receiving FDA approval to proceed with human clinical trials for its LIBERTY Endovascular Robotic Surgical System. The company has signed a clinical trial service agreement with a leading academic medical center and is completing biocompatibility tests. The stock saw heavy trading volume, significantly exceeding its 100-day average.

Portfolio Pulse from Erica Kollmann

June 03, 2024 | 3:36 pm

AMC

FFIE

GME

Dave Portnoy announced significant stakes in GameStop (GME) and AMC Entertainment (AMC), influenced by Roaring Kitty's recent social media activity. Both stocks saw initial gains but later dropped. Portnoy is also eyeing Faraday Future Intelligent Electric (FFIE) as his next investment.

Portfolio Pulse from Aaron Bry

June 03, 2024 | 3:36 pm

NTLA

Intellia Therapeutics (NASDAQ:NTLA) shares surged 11.2% after the company announced promising long-term data from its Phase 1 study of NTLA-2002, a CRISPR-based gene-editing therapy for hereditary angioedema (HAE). The single-dose treatment showed a 98% reduction in monthly HAE attacks and was well-tolerated with no severe side effects.

Portfolio Pulse from Dylan Berman

June 03, 2024 | 3:33 pm

ETHUSD

GBTC

The impending arrival of spot Ethereum ETFs has generated excitement in the crypto market. Analysts predict significant inflows and price movements for Ethereum (ETH), with estimates ranging from $1 billion to $3 billion in net inflows. Price scenarios for ETH by the end of 2024 range from $4,428 to $6,730, depending on market conditions and inflows.

Portfolio Pulse from Murtuza Merchant

June 03, 2024 | 3:30 pm

AGIO

Agios Pharmaceuticals shares are trading higher after the company reported that its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved its primary endpoint of transfusion reduction response.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:28 pm

GPCR

Structure Therapeutics Inc. (NASDAQ:GPCR) announced positive 12-week topline obesity data from its Phase 2a study of GSBR-1290, showing significant weight loss and favorable safety results. The company plans to submit an IND to the FDA in Q3 2024 and initiate a Phase 2b study in Q4 2024.

Portfolio Pulse from Vandana Singh

June 03, 2024 | 3:11 pm

NBIX

Neurocrine Biosciences shares are trading higher after the company presented positive data from its CAHtalyst Phase 3 Pediatric and Adult Studies, CAHtalog Registry, and disease- and glucocorticoid-related comorbidities data in CAH at ENDO 2024.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:10 pm